

Restoring Lives

2024 ENVIRONMENTAL, SOCIAL & GOVERNANCE HIGHLIGHTS

Integra at a Glance

Today, the Company has more than \$1.6 billion in global revenue, with market-leading brands sold in 120 countries. Integra manufactures and sells medical technologies and products in two reportable business segments: Codman Specialty Surgical, also known as CSS, and Tissue Technologies.


We have an advanced position in the medical device industry as a result of:

- Achieving no. 1 or 2 player in attractive markets
- Depth and breadth of portfolio and technologies
- Tenured, trusted salesforce and channels
- Global footprint for technology access and commercialization
- Strong balance sheet and financial discipline
- Systematic M&A aimed at accretive growth segments


REVENUE
FY2024

\$1.61B

BY PRODUCT CATEGORY



BY GEOGRAPHY



1989

Founded

4,396

Colleagues

24

Manufacturing sites
Established Global Centers of Excellence

3

Primary global
third-party logistics
distribution centers

120

Countries served


4,517

HCP and Customer
Touchpoints

Our Business Segments

Codman Specialty Surgical

Codman Specialty Surgical represents approximately two-thirds of our total revenue and consists of market-leading technologies and instrumentation for a wide range of specialties, such as neurosurgery, neurocritical care, otolaryngology, and ENT and skull-base procedures. Integra is the world leader in neurosurgery med tech, and our global scale allows us to offer solutions across multiple disease states like brain lesion surgery, including minimally invasive techniques; traumatic brain injury care and neuromonitoring; and hydrocephalus care. We are also one of the top providers of instruments used in precision, specialty and general surgical.



LEADING BRANDS

Codman®
DuraGen®
DuraSeal®
CUSA®

CereLink®
Mayfield®
Bactiseal®
Certas® Plus

New Product Innovation

\$27.6M
Revenue

+46%
Increase from 2023



Tissue Technologies

The Tissue Technologies segment generates about one-third of our overall revenue and focuses on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. This segment of our business represents the broadest set of regenerative technology platforms in the industry, ranging from highly engineered collagen technologies to bovine dermis, porcine and amniotic tissue, and bioreabsorbable matrix.



LEADING BRANDS

Integra® Dermal Regeneration Template
PriMatrix®
AmnioExcel®

SurgiMend®
MicroMatrix®
DuraSorb®
NeuraGen®

New Product Innovation

\$7.6M
Revenue

+262%
Increase from 2023



Integrated Growth Strategy

In 2024, Integra maintained its focus on the five pillars of our integrated growth strategy established in 2022. These pillars are made up of three growth drivers—levers that directly impact the Company's growth ambitions—and two enablers that make integrated growth possible. This approach continues to enable us to strengthen operational capacity and efficiency and accelerate innovation and growth, and in 2024 led to key accomplishments in each of the pillars.

DRIVING AN INTEGRATED GROWTH STRATEGY

Strengthening Operational Capability and Efficiency, Accelerating Innovation and Growth

GROWTH DRIVERS

Innovate for Outcomes



Grow International



Broaden Impact on Care Pathways



2024 ACCOMPLISHMENTS

Advanced PMA submission for DuraSorb® with completion of the IDE study (all subjects treated with follow-up completed)

Received PMA status of 'approvable pending GMP' from FDA for SurgiMend® PRS ABDM

Experienced strong demand for our differentiated portfolio of leading brands

Recertifications of EU MDR

Expanded international commercial footprint and portfolio

Advanced in-China-for-China manufacturing build-out

Announced transition of manufacturing of PriMatrix® and SurgiMend® to Braintree, Massachusetts, in the first half of 2026

Realized strong market uptake of CereLink®

Integrated the Acclarent acquisition successfully

Double-digit growth in cerebrospinal fluid management and wound reconstruction

ENABLERS

Drive Operations and Customer Excellence



Cultivate a High-Performance Culture



Strengthened supply chain capabilities to mitigate disruptions and enhance reliability

Made strategic investments in capacity expansion of our facilities and equipment to meet increasing demand and support future growth

Streamlined our processes and drove operational efficiencies

Matured to business resource groups (BRGs) from employee resource groups (ERGs)

Appointed Mojdeh Poul as president & CEO

2024 Highlights

ESG Ratings

22.8 ESG Risk Rating

Sustainalytics

AA ESG Rating

MSCI

as of 07/21/2025

C ESG Corporate Rating

ISS Corporate



Top 100 Corporate Publications


for the Integra LifeSciences 2023 Environmental, Social and Governance Report #89 worldwide

Silver Award

for excellence within its Competition Class on the development of Integra LifeSciences 2023 Environmental, Social and Governance Report

Environmental

2024 SCOPE 1, 2 AND 3



Implemented a carbon accounting SAAS solution in order to improve data collection and quality, and provide greater levels of transparency while leveraging industry best practices.

Continued to evaluate process improvements to reduce energy consumption in an effort to reduce Scope 1 emissions at our major manufacturing sites.

~34,700

Devices were maintained through our service and repair facilities

Social

7.6M+

Products sold

\$2.9M

In products donated

\$596K+

In grant donations by the Integra Foundation to **109 nonprofits**

80%

Participation rate in colleague engagement surveys


~1 in 5

Integra colleagues are members of a BRG

234

Events held by our **7 BRGs**

COLLEAGUES BY GENDER



Governance

100%

Of employees received Code of Conduct and anti-bribery and -corruption training

In 2024, we **formed our decarbonization steering committee and held our inaugural meeting with a diverse group of internal stakeholders** to help inform our overall decarbonization strategy.


50%

Of our board members are women

38%

Of our board members are from ethnically diverse backgrounds

BOARD DIVERSITY





INTEGRA LIFESCIENCES

1100 Campus Road, Princeton, New Jersey 08540

WWW.INTEGRALIFE.COM

INTEGRA 